RSV-F antibody Primary Antibody
Reactivity: Human
BR, ELISA, FACS, IP, WB
Host: Mouse
Monoclonal
Palivizumab
unconjugated
Catalog No. ABIN6730990
$360.00
Plus shipping costs $45.00
100 μL
local_shipping
Shipping to:
United States
Delivery in 7 to 8 Business Days
-
- Target
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
- Host
- Mouse
- Clonality
- Monoclonal
- Application
- Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
- Purpose
- Palivizumab is a humanised IgG1monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV).
- Specificity
- "Palivizumab is a humanised IgG1monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV)."
- Characteristics
- "This is a therapeutic antibody derived from Synagis and designed for research purposes.Palivizumab, the active ingredient of Synagis, is a humanised IgG1 monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV)." Palivizumab is a humanised IgG1κ monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.
Palivizumab serum concentrations of approximately 30 μg/ml have been shown to produce a 99% reduction in pulmonary RSV replication in the cotton rat model. - Purification
- The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml. (original drug Synagis 100 was diluted 1:100)
- Sterility
- Sterile
- Clone
- Palivizumab
-
anti-RSV-F (AA 1-529) antibody Primary Antibody
Reactivity: Respiratory Syncytial Virus (RSV) MN Host: Rabbit Monoclonal R338 unconjugated
-
- Application Notes
- Optimal dilution for a specific application should be determined by user
- Comment
Palivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells.
- Protocol
- Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- The dilutant is sterile PBS pH 7.4. No preservatives added
- Preservative
- Without preservative
- Handling Advice
- open only under sterile conditions
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
- Expiry Date
- 48 months
-
You are here: